Long-term follow-up of 90Y-ibritumomab-tiuxetan (90YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center
Crossref DOI link: https://doi.org/10.1038/bmt.2016.67
Published Online: 2016-04-04
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Philippe, L
Helias, P
Puyraveau, M
Boulahdour, H
Deconinck, E
Daguindau, E
Text and Data Mining valid from 2016-04-04
Version of Record valid from 2016-04-04
Article History
First Online: 4 April 2016
Competing interests
: The authors declare no conflict of interest.